

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number

New Application 10/702,302

Filing Date

herewith

First Named Inventor

Maag, Hans et al.

Art Unit

unassigned 1624

Examiner Name

unassigned K-Habek

Attorney Docket Number

R0151B-REG

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
KH	A-1	US-6,214,829	04-10-2001	Feenstra, et al.	
	A-2	US-6,225,312	05-01-2001	Feenstra, et al.	
	A-3	US-5,424,313	06-13-1995	Hartog, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^o
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
KH	B-1	WO 02/34754, A2	05-02-2002	Smithkline Beecham PLC (GB)		
	B-2	WO 02/02529, A1	01-10-2002	Knoll GmbH (DE)		
	B-3	WO 01/72725, A1	10-04-2001	COR Therapeutics, Inc. (US)		
	B-4	WO 01/57003, A1	08-09-2001	COR Therapeutics, Inc. (US)		
	B-5	WO 01/14330, A2	03-01-2001	Solvay Pharmaceuticals B.V. (NL)		
	B-6	WO 97/36893, A1	10-09-1997	Duphar International Research B.V. (NL)		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KH	C-1	FEENSTRA, Rolf W. et al., "New 1-Aryl-4-(biarylmethylene)piperazines as Potential Atypical Antipsychotics Sharing Dopamine D ₂ -Receptor and Serotonin 5-HT _{1A} -Receptor Affinities," <i>Bioorganic & Medicinal Chemistry Letters</i> , (2001) pp. 2345-2349, No. 11, Pergamon	

Examiner
SignatureDate
Considered

3/10/2000

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Doc. #122551v1